InvestorsHub Logo
Followers 154
Posts 2653
Boards Moderated 0
Alias Born 01/29/2004

Re: XenaLives post# 273863

Monday, 10/05/2020 12:08:24 PM

Monday, October 05, 2020 12:08:24 PM

Post# of 464087
Of no consequence whatsoever.

What if they have "anecdotal" CV data from the other trials?


As we know, "anecdotal" data, the experiences and data from individuals, whether in clinical trials or not, are utterly dismissed, disregarded, and rejected. Think not? Show to a "scientist" any of the videos of Australians being able to once again play the piano or paint, after taking blarcamesine for their Alzheimer's. "Sure, just a placebo effect; clear and simple. I've got to see compiled, analyzed data on hundreds of people, from replicated double-blind clinical human trials. Go away with this anecdotal stuff."

But, if you mean by "they" to be Anavex, that's even a stronger reason to conduct a solid murine test, to "confirm" those observations seen in humans. If cardiovascular health is shown to be facilitated by Anavex drugs in both rats and humans, full-scale human clinical trials will go forward.

Of course, what the Anavex principals actually know right now about their molecules is not being revealed; intelligently. First things first. "Scientists" and "the market" can only handle so much.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent AVXL News